PNC-27
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PNC-27 is an experimental anticancer peptide built around the p53 / HDM-2 axis. It fuses a fragment of the p53 protein (the residues that bind HDM-2) to a membrane-penetrating sequence, with the goal of killing cancer cells while sparing normal ones. It’s frequently lumped into “anti-aging / longevity” directories, but it’s really an anticancer / p53-restoration compound, not a longevity peptide proper.
What does it do in my body?
The peptide carries an HDM-2 binding domain that recognizes membrane-bound HDM-2 — a form of the protein that cancer cells display on their plasma membrane but normal cells largely don’t. PNC-27 binds it, then disrupts the membrane and the mitochondria, causing necrosis selectively in cancer cells. The selectivity claim — kills cancer cells, spares normal cells — is the whole pitch and recurs across the in-vitro literature.
How can it help me?
- Where the science stands: Strong in-vitro record, one human ex-vivo tissue study, one animal synergy study; zero randomized controlled trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No human safety data exists beyond one small ex-vivo tissue study and one human review of the mechanism class. There is no documented human side-effect profile to report.
Regulatory status: Research compound — not approved for human use. Tier D / encyclopedia-only: a genuinely interesting selective-cytotoxicity mechanism with real preclinical support, but no human clinical efficacy established and no place in a consumer-facing recommendation.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
None exists, and none should be implied. PNC-27 has no completed human-efficacy trials and no established dosing convention for human use. This is a research compound studied in cell culture and animal models, not a self-directed protocol candidate.
What should I avoid combining — and what's synergistic?
PNC-27 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
An experimental anticancer peptide with a genuinely interesting selective-cytotoxicity mechanism and real preclinical support — but no completed human-efficacy trial and no place in a consumer recommendation. Often mislabeled as an “anti-aging” peptide when it’s really an anticancer / p53-restoration compound.
| Class | Experimental anticancer peptide built on the p53/HDM-2 axis, fused to a membrane-penetrating sequence |
| Mechanism (one line) | Binds membrane-bound HDM-2 on cancer cells, disrupting the membrane and mitochondria to cause selective necrosis |
| Evidence base | Strong in-vitro record, one human ex-vivo tissue study, one animal synergy study; zero randomized controlled trials |
| Safety record | No completed human-efficacy trials; safety in humans not established |
| Regulatory status | Research compound; not approved for human use |
What it is
PNC-27 is an experimental anticancer peptide built around the p53 / HDM-2 axis. It fuses a fragment of the p53 protein (the residues that bind HDM-2) to a membrane-penetrating sequence, with the goal of killing cancer cells while sparing normal ones. It’s frequently lumped into “anti-aging / longevity” directories, but it’s really an anticancer / p53-restoration compound, not a longevity peptide proper.
How it works
The peptide carries an HDM-2 binding domain that recognizes membrane-bound HDM-2 — a form of the protein that cancer cells display on their plasma membrane but normal cells largely don’t. PNC-27 binds it, then disrupts the membrane and the mitochondria, causing necrosis selectively in cancer cells. The selectivity claim — kills cancer cells, spares normal cells — is the whole pitch and recurs across the in-vitro literature.
What the research shows
The evidence is graded “moderate” (17 studies, claims 3 human), but the underlying body is overwhelmingly cell-based, with one ex-vivo human-tissue study and one animal synergy study. The credible, on-topic citations (all):
- Sarafraz-Yazdi E, et al. — Ann Clin Lab Sci 2015 ex-vivo case-series: PNC-27 inhibited growth and was cytotoxic to patient-derived epithelial ovarian cancer cells in a dose-dependent way. 26663795
- Alagkiozidis I, et al. — Ann Clin Lab Sci 2017: PNC-27 + paclitaxel showed a synergistic reduction in ovarian tumor growth in vivo. 28667027
- Pincus MR, et al. — Curr Pharm Des 2011 review — PNC-27/PNC-28 induce tumor-cell necrosis across multiple cancer types without harming normal cells. 21728981
- Krzesaj P, et al. — Ann Clin Lab Sci 2024 — PNC-27 binds membrane HDM-2 and disrupts mitochondria → cell necrosis. 38802154
- Thadi A, et al. — Anticancer Res 2020/2021 — selective necrosis of leukemia cells and colon-cancer stem cells via membrane HDM-2, sparing normal hematopoietic/epithelial cells. 32878773 · 33419797
There are zero randomized controlled trials and no completed human-efficacy trials. Source-integrity note: the directory profile this article draws from originally included two unrelated papers in its “key studies” table for PNC-27 (a Nigeria maternal-healthcare cohort and a Rome air-pollution study) — they have nothing to do with PNC-27 and are excluded here; treat any “3 human trials” count with caution.
Real-world protocol
None exists, and none should be implied. PNC-27 has no completed human-efficacy trials and no established dosing convention for human use. This is a research compound studied in cell culture and animal models, not a self-directed protocol candidate.
Side effects & management
No human safety data exists beyond one small ex-vivo tissue study and one human review of the mechanism class. There is no documented human side-effect profile to report.
Regulatory status
Research compound — not approved for human use. Tier D / encyclopedia-only: a genuinely interesting selective-cytotoxicity mechanism with real preclinical support, but no human clinical efficacy established and no place in a consumer-facing recommendation.